Boost for Biocad's biosimilars as Russia approves first Herceptin copy
Russia’s first approved trastuzumab biosimilar will be priced at least 10% cheaper than Roche’s Herceptin, according to developer Biocad.
Archives for January 22, 2016
In good Cell Culture Company? Biovest spin-out to compete in consolidated sector
Consolidation among bioprocessing tech companies is set to continue, according to Cell Culture Company - the bioreactor and contract manufacturing firm set to spin-out from Biovest.
Biosimilar developer Oncobiologics files for $115m IPO
Oncobiologics has filed an initial public offering looking to raise $115m to further develop its biosimilar mAb pipeline.